Skip to main content
Clinical Trials/NCT04101448
NCT04101448
Unknown
Not Applicable

Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients

Assiut University1 site in 1 country100 target enrollmentSeptember 30, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchiectasis
Sponsor
Assiut University
Enrollment
100
Locations
1
Primary Endpoint
Prevalence of Bronchiectasis in COPD
Last Updated
6 years ago

Overview

Brief Summary

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Detailed Description

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Registry
clinicaltrials.gov
Start Date
September 30, 2019
End Date
September 30, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Aliae AR Mohamed Hussein

Professor of Pulmonology

Assiut University

Eligibility Criteria

Inclusion Criteria

  • COPD patients based on GOLD 2019 criteria, stable or in exacerbation

Exclusion Criteria

  • acute pneumonia within 2 months
  • malignancy
  • congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome).
  • Pregnancy

Outcomes

Primary Outcomes

Prevalence of Bronchiectasis in COPD

Time Frame: 1 year

percentage of bronchiectasis diagnosed by CT chest in COPD patients

Secondary Outcomes

  • impact of bronchiectasis on COPD intensive care admission(1 year)
  • impact of bronchiectasis on COPD exacerbations(1 year)
  • impact of bronchiectasis on COPD hospitalization(1 year)

Study Sites (1)

Loading locations...

Similar Trials